Drug Profile
Research programme: antimalarials - Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Broad Institute; Genzyme Corporation; Harvard University
- Developer Broad Institute; Harvard University; Medicines for Malaria Venture; Sanofi
- Class
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Heat-shock protein inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 31 Dec 2010 This programme is still in active development